X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AK002 (lirentelimab) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8. It is being evaluated in phase 2 clinical trials for the treatment of atopic dermatitis and chronic spontaneous urticaria.
Lead Product(s): Lirentelimab
Therapeutic Area: Dermatology Product Name: AK002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6, an inhibitory receptor selectively expressed on mast cells. Binding of AK006 to Siglec-6 activates the native inhibitory function of the receptor which in turn reduces mast cell activation.
Lead Product(s): AK006
Therapeutic Area: Immunology Product Name: AK006
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
AK007 is a humanized Siglec-10 antagonist antibody designed to block Siglec-10 interaction with all known ligands (CD24, CD52, and VAP-1). Allakos is currently conducting additional pre-clinical studies with AK007.
Lead Product(s): AK007
Therapeutic Area: Oncology Product Name: AK007
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
AK002 (Lirentelimab) selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response.
Lead Product(s): Lirentelimab
Therapeutic Area: Gastroenterology Product Name: AK002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
The trial met its histologic co-primary endpoint, but it did not achieve statistical significance for AK002 (lirentelimab) on the patient reported symptomatic co-primary endpoint, in both the intent to treat (ITT) population and in a prespecified subpopulation.
Lead Product(s): Lirentelimab
Therapeutic Area: Gastroenterology Product Name: AK002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
In this study, lirentelimab was generally well tolerated and the only treatment emergent adverse event occurring more frequently on lirentelimab than on placebo was mild to moderate infusion-related reactions.
Lead Product(s): Lirentelimab
Therapeutic Area: Gastroenterology Product Name: AK002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils, which is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD).
Lead Product(s): Lirentelimab
Therapeutic Area: Gastroenterology Product Name: AK002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
A Phase 3 Study of lirentelimab in patients with EG/EoD and a Phase 2/3 Study in patients with eosinophilic esophagitis are currently underway. Data from these studies are expected in the fourth quarter of 2021.
Lead Product(s): Lirentelimab
Therapeutic Area: Gastroenterology Product Name: AK002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
The Company’s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE).
Lead Product(s): Lirentelimab
Therapeutic Area: Gastroenterology Product Name: AK002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Lirentelimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Drug has been studied in a prospective, multi-center, randomized, double-blind, placebo controlled, Phase 2 Study in patients with EG and/or EoD (ENIGMA).
Lead Product(s): Lirentelimab
Therapeutic Area: Gastroenterology Product Name: AK002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
